FDA Approval Sought for Crovalimab for Paroxysmal Nocturnal

The FDA has accepted a biologics license application seeking the approval of crovalimab for use in patients with paroxysmal nocturnal hemoglobinuria.

Related Keywords

Levi Garraway , Genentech , Global Product Development , Key Objectives , Eligibility Criteria , Bend Points , Hematologic Oncology , News ,